KR20240024063A - Pkc-세타 조정제 - Google Patents

Pkc-세타 조정제 Download PDF

Info

Publication number
KR20240024063A
KR20240024063A KR1020237041626A KR20237041626A KR20240024063A KR 20240024063 A KR20240024063 A KR 20240024063A KR 1020237041626 A KR1020237041626 A KR 1020237041626A KR 20237041626 A KR20237041626 A KR 20237041626A KR 20240024063 A KR20240024063 A KR 20240024063A
Authority
KR
South Korea
Prior art keywords
alkyl
group
hydrogen
mmol
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041626A
Other languages
English (en)
Korean (ko)
Inventor
피터 레이
앤토니 브레들리
사이먼 리차즈
카타리나 산토스
제레미 베즈나드
제롬 메네이롤
버지니 수차우드
Original Assignee
엑스사이언티아 에이아이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스사이언티아 에이아이 리미티드 filed Critical 엑스사이언티아 에이아이 리미티드
Publication of KR20240024063A publication Critical patent/KR20240024063A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Optical Communication System (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237041626A 2021-05-06 2022-05-06 Pkc-세타 조정제 Pending KR20240024063A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2106486.0 2021-05-06
GB202106486 2021-05-06
PCT/GB2022/051167 WO2022234299A1 (en) 2021-05-06 2022-05-06 Pkc-theta modulators

Publications (1)

Publication Number Publication Date
KR20240024063A true KR20240024063A (ko) 2024-02-23

Family

ID=82100804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041626A Pending KR20240024063A (ko) 2021-05-06 2022-05-06 Pkc-세타 조정제

Country Status (14)

Country Link
US (1) US20240239794A1 (https=)
EP (1) EP4334316A1 (https=)
JP (1) JP2024518447A (https=)
KR (1) KR20240024063A (https=)
CN (1) CN117295738A (https=)
AU (1) AU2022269348A1 (https=)
BR (1) BR112023022883A2 (https=)
CA (1) CA3214088A1 (https=)
CL (1) CL2023003247A1 (https=)
CO (1) CO2023015005A2 (https=)
IL (1) IL307669A (https=)
MX (1) MX2023013012A (https=)
PE (1) PE20250019A1 (https=)
WO (1) WO2022234299A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
CN118772140B (zh) * 2023-04-07 2026-04-17 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途
WO2025255294A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use
WO2025255298A1 (en) * 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Pkc-theta inhibitors, compositions, and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924762A (en) * 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
GB0920382D0 (en) 2009-11-20 2010-01-06 Univ Dundee Design of molecules
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
US9556126B2 (en) 2013-12-20 2017-01-31 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
AU2020284742B2 (en) * 2019-05-28 2026-03-05 Mankind Pharma Ltd. Novel compounds for inhibition of Janus Kinase 1
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators

Also Published As

Publication number Publication date
IL307669A (en) 2023-12-01
CA3214088A1 (en) 2022-11-10
WO2022234299A1 (en) 2022-11-10
AU2022269348A1 (en) 2023-10-26
CN117295738A (zh) 2023-12-26
MX2023013012A (es) 2024-03-25
CL2023003247A1 (es) 2024-04-26
BR112023022883A2 (pt) 2024-01-23
US20240239794A1 (en) 2024-07-18
CO2023015005A2 (es) 2024-02-05
JP2024518447A (ja) 2024-05-01
EP4334316A1 (en) 2024-03-13
PE20250019A1 (es) 2025-01-07

Similar Documents

Publication Publication Date Title
TWI902789B (zh) 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法
JP6775645B2 (ja) Ｐｉｍキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
KR102614939B1 (ko) 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
KR20240024063A (ko) Pkc-세타 조정제
AU2011305568B2 (en) Imidazotriazinone compounds
CA2924619C (en) 4-azaindole derivatives
TW202115025A (zh) 作為hpk1抑制劑之胺基吡化合物及其用途
KR20240024062A (ko) Pkc-세타 조정제
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
TW202140478A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶（btk）及其使用方法
AU2016367261A1 (en) Therapeutic inhibitory compounds
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
WO2016168641A1 (en) Tricyclic modulators of tnf signaling
TW202233624A (zh) Ｂｔｋ抑制劑
KR20260040148A (ko) Irak 분해제 및 이의 용도
TW202438054A (zh) 作為ＭＴＡ－協同ＰＲＭＴ５抑制劑的５－胺基－６，８－二氫－１Ｈ－呋喃并［３，４－ｄ］吡咯并［３，２－ｂ］吡啶－２－甲醯胺衍生物
KR20240148322A (ko) 이작용성 아릴설폰아미드 화합물
IL303356A (en) N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1 - CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE derivatives as IRAK4 inhibitors for the treatment of asthma
CN118344386A (zh) 取代桥环类抑制剂及其制备方法和应用
KR20250137706A (ko) Nlrp3 억제제
JP2025502802A (ja) Ｉｒａｋ４阻害剤としてのヘテロアリール化合物、その組成物および用途
CN121464138A (zh) Mllt1和/或mllt3的protac降解剂
WO2026060424A1 (en) Akt degrader compounds and uses thereof
CN121057733A (zh) 吡啶并咪唑酮化合物、其制备及其治疗用途
TW202608884A (zh) 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶（btk）及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231201

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250502

Comment text: Request for Examination of Application